#### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

#### **Listing of Claims:**

### 1. (Currently Amended) A compound having Formula 1:

$$\begin{array}{c} R_4 \\ N - Z_1 - R_1 \\ N \\ N \\ R_2 \end{array}$$
 Formula 1

a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein

 $R_1$  is hydrogen; cyclo-( $C_3$ - $C_6$  alkyl)-methyl; straight or branched chain  $C_1$ - $C_7$  alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; sulfonamide;  $C_1$ - $C_6$  alkoxy; ( $C_1$ - $C_6$ )-alkyl-oxy-( $C_1$ - $C_6$ )alkoxy; ( $C_1$ - $C_6$ )-alkyl-oxy-( $C_1$ - $C_6$ )alkyl; mono- or di( $C_1$ - $C_6$  alkyl)amino, mono- or di( $C_1$ - $C_6$  alkyl)amino( $C_1$ - $C_6$  alkyl); or phenyl or heteroaryl ring which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, sulfonamide, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkoxy, -S( $C_1$ - $C_6$  alkyl), mono- or di( $C_1$ - $C_6$  alkyl)amino( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester;

 $R_2$  is straight or branched chain  $C_1$ - $C_7$  alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; cyclo- $(C_3$ - $C_6$  alkyl)-methyl;  $C_1$ - $C_6$  alkoxy;  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ - $(C_1$ - $(C_1$ - $C_6)$ - $(C_1$ -

cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl, mono- or di( $C_1$ - $C_6$  alkyl) amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, mono- or di( $C_1$ - $C_6$ 

R<sub>3</sub> is hydrogen; carboxylic acid or ester; straight or branched chain C<sub>1</sub>-C<sub>6</sub> alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkoxy,  $(C_1-C_6)$ -alkyl-oxy- $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$ -alkyl-oxy- $(C_1-C_6)$ alkyl, mono- or  $di(C_1-C_6 \text{ alkyl})$ amino, amino $(C_1-C_6 \text{ alkyl})$ ,  $-S(C_1-C_6 \text{ alkyl})$ , or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C1-C6 alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>- $C_6) alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6) alkyl, mono- \ or \ di(C_1-C_6 \ alkyl) amino, \ amino(C_1-C_6 \ alkyl),$ -S(C<sub>1</sub>-C<sub>6</sub> alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkyl, mono- or di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, mono- or di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), or carboxylic acid or ester;

R<sub>4</sub> is hydrogen; straight or branched chain C<sub>1</sub>-C<sub>6</sub> alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkyl; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkyl, mono- or di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, amino(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C<sub>1</sub>- $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6$ )alkoxy,  $(C_1-C_6)$ -alkyl-oxy- $(C_1-C_6)$ alkyl, mono- or  $di(C_1-C_6)$ alkyl)amino, amino $(C_1-C_6)$ alkyl, -S(C<sub>1</sub>-C<sub>6</sub> alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>- $C_6$ ) alkyl, mono- or di( $C_1$ - $C_6$  alkyl) amino, mono- or di( $C_1$ - $C_6$  alkyl) amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$ alkyl), or carboxylic acid or ester; or form a 3-7 member heteroalkyl or alkyl with  $Z_1$  or  $R_1$ ;

X is [[N or]] CH

 $Z_1$  is

$$\begin{array}{c}
\begin{pmatrix}
R_5 \\
C \\
R_6 \\
M
\end{pmatrix}, \quad C \\
C \\
R_7$$
or
$$\begin{array}{c}
O \\
\parallel \\
R_7
\end{array}$$

wherein

each occurrence of R<sub>5</sub> and R<sub>6</sub> is independently hydrogen straight or branched chain C<sub>1</sub>-C<sub>6</sub> alkyl, sulfonamide, or halogen;

m is 0, 1, or 2; and

R<sub>7</sub> is hydrogen; straight or branched chain C<sub>1</sub>-C<sub>6</sub> alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro,

cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, dior trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; and

#### $Z_2$ is

#### wherein

each occurrence of R<sub>8</sub> and R<sub>9</sub> is independently straight or branched chain C<sub>1</sub>-C<sub>6</sub> alkyl, sulfonamide, or halogen;

n is 0, 1, or 2; and

 $R_{10}$ - $R_{13}$  are each independently hydrogen; straight or branched chain  $C_1$ - $C_6$  alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ alkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ alkyl, mono- or di $(C_1$ - $C_6$  alkyl)amino, amino $(C_1$ - $C_6$  alkyl), -

Application No.: 10/658,121

 $S(C_1-C_6 \text{ alkyl})$ , or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $C_1-C_6$  perfluoroalkyl,  $C_1-C_6$  perfluoroalkoxy,  $(C_1-C_6)$ -alkyl-oxy- $(C_1-C_6)$ -alkyl-oxy- $(C_1-C_6)$ -alkyl, mono- or di $(C_1-C_6 \text{ alkyl})$ amino, amino $(C_1-C_6 \text{ alkyl})$ , - $S(C_1-C_6 \text{ alkyl})$ , or carboxylic acid or ester;

and wherein, when R<sub>3</sub> is hydrogen and R<sub>4</sub> is hydrogen, or when R<sub>3</sub> and R<sub>1</sub> are hydrogen and Z<sub>1</sub> is

wherein m is 0, the combination of  $Z_2$ - $R_2$  is not hydrogen, hydroxy, halogen, hydroxyamide, amino, hydroxyalkyl, aminoalkylamide, alkylamide, arylamide or alkoxy, or wherein when  $R_3$  is hydrogen,  $R_4$  and  $Z_1$ , or  $R_4$  and  $R_1$  do not form a morpholino, piperazinyl, or 1,4-diazepanyl group when the combination of  $Z_2$ - $R_2$  is hydrogen, hydroxy, halogen, hydroxyamide, amino, hydroxyalkyl, aminoalkylamide, alkylamide, arylamide or alkoxy.

# 2. (Currently Amended) A compound having Formula 2:

$$R_4$$
  $N$   $Z_1$   $R_1$  Formula 2  $R_2$   $Z_2$   $R_3$ 

a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixtures thereof, wherein

R<sub>1</sub> is phenyl or heteroaryl ring which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, sulfonamide, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub>

alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy, -S( $C_1$ - $C_6$  alkyl), mono- or di( $C_1$ - $C_6$  alkyl)amino, mono- or di( $C_1$ - $C_6$  alkyl)amino( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester;

 $R_2$  is phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkoxy,  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )-alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, mono- or di( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; and wherein  $R_2$  can form a 3-7 heteroalkyl or alkyl with  $R_{10}$ ,  $R_{11}$ , or  $R_{12}$ ;

R<sub>3</sub> is hydrogen; or carboxylic acid or ester;

 $R_4$  is hydrogen; straight or branched chain  $C_1$ - $C_6$  alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; or  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkyl;

X is [[N or]] CH

 $Z_1$  is

$$\begin{array}{c}
\begin{pmatrix}
R_5 \\
I \\
C \\
I \\
R_7
\end{array}$$

wherein

each occurrence of R<sub>5</sub> and R<sub>6</sub> is independently hydrogen straight or branched chain C<sub>1</sub>-C<sub>6</sub> alkyl, sulfonamide, or halogen;

m is 0, 1, or 2; and

 $\mathbb{Z}_2$  is

wherein

 $R_{10}$ - $R_{13}$  are each independently hydrogen; straight or branched chain  $C_1$ - $C_6$  alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ alkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -  $S(C_1$ - $C_6$  alkyl), or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), - $S(C_1$ - $C_6$  alkyl), or carboxylic acid or ester;

Application No.: 10/658,121

and wherein, when R<sub>3</sub> is hydrogen and R<sub>4</sub> is hydrogen, or when R<sub>3</sub> and R<sub>1</sub> are hydrogen and Z<sub>1</sub> is

 $R_0$  wherein m is 0, the combination of  $Z_2$ - $R_2$  is not hydrogen, hydroxy, halogen, hydroxyamide, amino, hydroxyalkyl, aminoalkylamide, alkylamide, arylamide or alkoxy, or

wherein when  $R_3$  is hydrogen,  $R_4$  and  $Z_1$ , or  $R_4$  and  $R_1$  do not form a morpholino, piperazinyl, or 1,4-diazepanyl group when the combination of  $Z_2$ - $R_2$  is hydrogen, hydroxy, halogen, hydroxyamide, amino, hydroxyalkyl, aminoalkylamide, alkylamide, arylamide or alkoxy.

## 3. (Currently Amended) A compound having Formula 3:

a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixtures thereof, wherein

 $R_1$  is hydrogen; cyclo-( $C_3$ - $C_6$  alkyl)-methyl; straight or branched chain  $C_1$ - $C_7$  alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; sulfonamide;  $C_1$ - $C_6$  alkoxy; ( $C_1$ - $C_6$ )-alkyl-oxy-( $C_1$ - $C_6$ )alkoxy; ( $C_1$ - $C_6$ )-alkyl-oxy-( $C_1$ - $C_6$ )alkyl; mono- or di( $C_1$ - $C_6$  alkyl)amino, mono- or di( $C_1$ - $C_6$  alkyl)amino( $C_1$ - $C_6$  alkyl); or phenyl or heteroaryl ring which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, sulfonamide, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkoxy, -S( $C_1$ - $C_6$  alkyl), mono- or di( $C_1$ - $C_6$  alkyl)amino, mono- or di( $C_1$ - $C_6$  alkyl)amino( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester;

R<sub>2</sub> is straight or branched chain C<sub>1</sub>-C<sub>7</sub> alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; cyclo-(C<sub>3</sub>-C<sub>6</sub> alkyl)-methyl; C<sub>1</sub>-C<sub>6</sub>  $alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy; (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl; phenyl \ or \ heteroaryl$ which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkoxy,  $(C_1-C_6)$ -alkyl-oxy- $(C_1-C_6)$ alkoxy,  $(C_1-C_6)$ -alkyl-oxy- $(C_1-C_6)$ alkyl, mono- or  $di(C_1-C_6)$ alkyl)amino, amino(C1-C6 alkyl), -S(C1-C6 alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ alkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ - $(C_1$ - $C_6)$ - $(C_1$ - $(C_1$ - $C_6)$ - $(C_1$ -(C $C_6$ )alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 perfluoroalkyl, C1-C6  $perfluoroalkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkoxy, (C_1-C_6)-alkyl-oxy-(C_1-C_6)alkyl, mono-oral context of the context o$  $di(C_1-C_6 \text{ alkyl})$ amino, mono- or  $di(C_1-C_6 \text{ alkyl})$ amino $(C_1-C_6 \text{ alkyl})$ , -S $(C_1-C_6 \text{ alkyl})$ , or carboxylic acid or ester; and wherein R<sub>2</sub> can form a 3-7 heteroalkyl or alkyl with R<sub>12</sub>;

R<sub>3</sub> is hydrogen; carboxylic acid or ester; straight or branched chain C<sub>1</sub>-C<sub>6</sub> alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkyl, mono- or di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, amino(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkyl, mono- or di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino, amino(C<sub>1</sub>-C<sub>6</sub> alkyl), -S(C<sub>1</sub>-C<sub>6</sub> alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub>

perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ alkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ alkyl, mono- or di $(C_1$ - $C_6$  alkyl)amino, mono- or di $(C_1$ - $C_6$  alkyl), or carboxylic acid or ester;

R<sub>4</sub> is hydrogen; straight or branched chain C<sub>1</sub>-C<sub>6</sub> alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkyl; phenyl or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>- $C_6$ )alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; phenyoxy phenyl where each phenyl may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C1- $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6$ ) alkoxy,  $(C_1-C_6)$  -alkyl-oxy- $(C_1-C_6)$  alkyl, mono- or  $di(C_1-C_6)$  alkyl) amino, amino  $(C_1-C_6)$  alkyl, -S(C<sub>1</sub>-C<sub>6</sub> alkyl), or carboxylic acid or ester; phenyl or heteroaryl piperazine where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>6</sub> perfluoroalkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)-alkyl-oxy-(C<sub>1</sub>- $C_6$ )alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, mono- or di( $C_1$ - $C_6$  alkyl)amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$ alkyl), or carboxylic acid or ester; or form a 3-7 member heteroalkyl or alkyl with  $Z_1$  or  $R_1$ ;

X is [[N or]] CH

 $Z_1$  is

wherein

each occurrence of R<sub>5</sub> and R<sub>6</sub> is independently hydrogen straight or branched chain C<sub>1</sub>-C<sub>6</sub> alkyl, sulfonamide, or halogen;

m is 0, 1, or 2; and

 $R_7$  is hydrogen; straight or branched chain  $C_1$ - $C_6$  alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl-oxy- $(C_1$ - $C_6)$ -alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy, ( $C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkoxy, ( $C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkyl, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; and

wherein  $R_{12}$  and  $R_{13}$  are each independently hydrogen; straight or branched chain  $C_1$ - $C_6$  alkyl; phenyl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkoxy, mono- or di( $C_1$ - $C_6$  alkyl)amino, amino( $C_1$ - $C_6$  alkyl), -S( $C_1$ - $C_6$  alkyl), or carboxylic acid or ester; or heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  perfluoroalkyl,  $C_1$ - $C_6$  perfluoroalkoxy,  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ )alkoxy,  $(C_1$ - $C_6$ )-alkyl-oxy- $(C_1$ - $C_6$ ) alkyl), or carboxylic acid or ester.

4. (Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-chloro-phenyl)-urea.

- 5. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-phenyl)-urea.
- 6. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-methoxy-phenyl)-urea.
- 7. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.
- 8. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.
- 9. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-trifluoromethyl-phenyl)-urea.

- 10. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-trifluoromethoxy-phenyl)-urea.
- 11. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-methylsulfanyl-phenyl)-urea.
- 12. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[Methyl-(4-methyl-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-methylsulfanyl-phenyl)-urea.
- 13. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-Chloro-phenyl)-3-(3-{8-[methyl-(4-methyl-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.
- 14. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[Methyl-(4-methyl-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.

- 15. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-Chloro-phenyl)-3-{3-[8-(3,4-dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.
- 16. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(3,4-Dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methylsulfanyl-phenyl)-urea.
- 17. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(3,4-Dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-o-tolyl-urea.
- 18. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(3,4-Dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methoxy-phenyl)-urea.
- 19. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 8-[(4-Chloro-benzyl)-methyl-amino]-6-{3-[3-(2-trifluoromethyl-phenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester.

- 20. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 8-[(4-Chloro-benzyl)-methyl-amino]-6-[3-(3-o-tolyl-ureido)-phenyl]-imidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester.
- 21. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 8-[(4-Chloro-benzyl)-methyl-amino]-6-{3-[3-(4-chloro-phenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester.
- 22. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[methyl-(4-methyl-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.
- 23. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-4-fluoro-phenyl)-urea.
- 24. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-benzyl)-3-(4-chloro-phenyl)-urea.

- 25. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-benzyl)-3-(3-chloro-4-fluoro-phenyl)-urea.
- 26. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-ethyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.
- 27. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal-form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-ethyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.
- 28. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-ethyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-4-fluoro-phenyl)-urea.
- 29. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-propyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.

- 30. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-propyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-4-fluoro-phenyl)-urea.
- 31. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[Butyl-(4-chloro-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.
- 32. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-propyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.
- 33. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-propyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.
- 34. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[Butyl-(4-chloro-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.

- 35. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[Butyl-(4-chloro-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.
- 36. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[Butyl-(4-chloro-benzyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-chloro-4-fluoro-phenyl)-urea.
- 37. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.
- 38. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-o-tolyl-urea.
- 39. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(Benzyl-methyl-amino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(4-chlorophenyl)-urea.

- 40. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-trifluoromethoxy-phenyl)-urea.
- 41. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(5-fluoro-2-trifluoromethyl-phenyl)-urea.
- 42. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3,5-dichloro-phenyl)-urea.
- 43. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3,4-dichloro-phenyl)-urea.
- 44. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(2-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.

- 45. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(Methyl-pyridin-4-ylmethyl-amino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.
- 46. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-Chloro-benzyl)-3-(3-{8-[(4-chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.
- 47. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-(2-methoxy-ethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-phenyl)-urea.
- 48. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-(2-methoxy-ethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.
- 49. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-(2-methoxy-ethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(4-chloro-3-fluoro-phenyl)-urea.

- 50. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-(2-methoxy-ethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-[4-(4-methyl-piperazin-1-ylmethyl)-phenyl]-urea.
- 51. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is (2-Methoxy-benzyl)-{6-[3-(4-methoxy-benzylamino)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine.
- 52. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{4-[8-(2-Methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-phenylurea.
- 53. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(2-Chloro-phenyl)-3-{4-[8-(2-methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.
- 54. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{4-[8-(2-Methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methoxy-phenyl)-urea.

- 55. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{4-[8-(2-Methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-methoxy-phenyl)-urea.
- 56. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is N-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzenesulfonamide.
- 57. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is N-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide.
- 58. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 4-Chloro-N-(3-{8-[(4-chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide.
- 59. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 2-Chloro-N-(3-{8-[(4-chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide.

- 60. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is (4-{8-[(3-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-piperidin-1-yl-methanone.
- 61. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is (4-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-piperidin-1-yl-methanone.
- 62. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 4-{6-[4-(Piperidine-1-carbonyl)-phenyl]-imidazo[1,2-a]pyrazin-8-ylamino}-benzoic acid ethyl ester.
- 63. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 4-(6-{3-[3-(4-Chloro-phenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester.
- 64. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 4-(6-{3-[3-(2-Methylsulfanyl-phenyl)-ureido]-phenyl}-imidazo[1,2-a]pyrazin-8-ylamino)-benzoic acid ethyl ester.

- 65. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(4-Chloro-benzyl)-methyl-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(2-methylsulfanyl-phenyl)-urea.
- 66. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is {4-[8-(4-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-piperidin-1-yl-methanone.
- 67. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrugthereof, wherein the compound is 3-Methoxy-N-{3-[8-(2-methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-benzamide.
- 68. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 2-Methoxy-N-{3-[8-(2-methoxy-benzylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-benzamide.
- 69. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.

- 70. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-Chloro-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.
- 71. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-[3-(8-Phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea.
- 72. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(2-Chloro-5-trifluoromethyl-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.
- 73. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-Chloro-phenyl)-3-{3-[8-(4-chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.
- 74. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(4-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.

- 75. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(3-chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.
- 76. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-Chloro-phenyl)-3-{3-[8-(3-chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.
- 77. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(3-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.
- 78. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(2-chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.
- 79. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-[3-(8-Phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-3-(4-trifluoromethyl-phenyl)-urea.

- 80. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[(pyridin-2-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.
- 81. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-Chloro-phenyl)-3-(3-{8-[(pyridin-3-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.
- 82. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[(pyridin-3-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.
- 83. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-Chloro-phenyl)-3-(3-{8-[(pyridin-4-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.
- 84. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form; diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(Pyridin-4-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.

- 85. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-(3-{8-[(pyridin-4-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.
- 86. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(Pyridin-4-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.
- 87. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(pyridin-4-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.
- 88. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(4-Chloro-phenyl)-3-(3-{8-[(pyridin-2-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea.
- 89. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-{8-[(Pyridin-2-ylmethyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea.

- 90. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(2-Methoxy-6-methyl-phenyl)-3-{3-[8-(pyridin-4-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.
- 91. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(2-Methoxy-5-methyl-phenyl)-3-[3-(8-phenylamino-imidazo[1,2-a]pyrazin-6-yl)-phenyl]-urea.
- 92. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(3-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methoxy-5-methyl-phenyl)-urea.
- 93. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(2-Chloro-phenylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(2-methoxy-5-methyl-phenyl)-urea.
- 94. (Withdrawn Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{3-[8-(Pyridin-3-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-3-(3-trifluoromethyl-phenyl)-urea.

Attorney Docket No. 09580.0006-00000

Application No.: 10/658,121

95. (Withdrawn - Currently Amended) A compound as in claim 1[[,]] or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-(3-Chloro-4-fluoro-phenyl)-3-{3-[8-(pyridin-3-ylamino)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

- 96. (Withdrawn) A compound or salt according to claims 1 to 95, wherein in an in vitro assay of kinase modulation, the compound exhibits a IC<sub>50</sub> value less than or equal to 25 micromolar.
- 97. (Withdrawn) A pharmaceutical composition comprising a compound or salt according to claims 1 to 95, combined with at least one pharmaceutically acceptable carrier or excipient.
- 98. (Withdrawn) A method of treating a kinase-implicated condition in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound or salt of claims 1 to 95.
- 99. (Withdrawn) The method of claim 98, wherein the mammal is a human.
- 100. (Withdrawn) The method of claim 98, wherein the mammal is a dog or cat.
- 101. (Withdrawn) A method for identifying a kinase, comprising contacting an organism, cell, or preparation comprising the kinase with compound or salt according to claim 1, and detecting modulation of an activity of the kinase.